To further investigate the role of ESCO2 in the DDR in colorectal cancer, we stably knocked down ESCO2 in HCT116 cells (ESCO2 KD HCT116) and monitored γH2AX foci, a biomarker of DSB damage, using an immunofluorescence assay 12 h after bleomycin treatment. Here, ESCO2 is linked to colorectal cancer.